Portnoy Law: Lawsuit Filed On Behalf of Johnson & Johnson Consumer, Inc. Investors

Click here to join the case

Investors are encouraged to contact attorney Lesley F. Portnoy , to determine eligibility to participate in this action, by phone 310-692-8883 or email , or click here to join the case.

It is alleged in this complaint that J&J failed to include labeling informing consumers that the sunscreens may contain benzene as an active or inactive ingredient, which rendered the products misbranded, adulterated and unlawful for sale. It is also alleged in this complaint that J&J's conduct caused economic damages to the plaintiffs, who had relied on the ingredient list and advertising when deciding whether to purchase the sunscreen.

J&J admitted on July 14, 2021 that the products were unfit to sell due to unsafe levels of benzene, initiating a voluntary recall of five aerosol sunscreens. All lots of these five products have been recalled by J&J.

"Johnson & Johnson continued to market these sunscreen products as safe and healthy for consumers after being alerted to dangerous levels of a known, cancer-causing chemical," said Keller Lenkner Partner Warren Postman. "Companies that knowingly sell cancer-causing products to the public should face serious consequences for their actions, and we will pursue all available remedies for consumers who were injured by Johnson & Johnson's disregard for public health."

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Seegnal (TSXV:SEGN)

Seegnal Presents Real-World Evidence on Reducing Fall Risk in Geriatric Patients at Caltcm Summit

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in AI-enhanced prescription intelligence, today announced real-world clinical results demonstrating how medication governance may reduce fall-risk drivers in older adults -- a significant clinical and financial challenge... Keep Reading...
Scientists working in a modern medical research laboratory.

Pathways to Commercialising Biotech Innovations

In the medical technology industry, innovation is only the first step. While key to long-term success, innovation is only as good as a company’s commercialisation strategy. Once a technology has been developed and proven, the organisation must then embark on a process to commercialise it for... Keep Reading...
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at... Keep Reading...
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the... Keep Reading...
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries CommenceDownload the PDF here. Keep Reading...
Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities. The groundbreaking developments in antifungal treatments specifically targeting women's health issues... Keep Reading...

Interactive Chart

Latest Press Releases

Related News